The short version of HGF/c-Met fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-14. Anything still debated is marked as such rather than presented as settled.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Later, the mother demonstrates hunting techniques for the kittens to emulate. As they reach three to four weeks old, the kittens are gradually weaned and begin to eat solid food, with weaning usually complete by six to eight weeks. Kittens generally begin to lose their baby teeth around three months of age, and they have a complete set of adult teeth by nine months. Kittens live primarily on solid food after weaning, but they usually continue to suckle from time to time until separated from their mothers. Some mother cats will scatter their kittens as early as three months of age, while others continue to look after them until they approach sexual maturity. The sex of kittens is usually easy to determine at birth. By six to eight weeks, this becomes harder because of the growth of fur in the genital region. The male's urethral opening is round, whereas the female's urethral opening is a slit. Another marked difference is the distance between anus and urethral opening, which is greater in males than in females.
Heseltine said that his statement that further investment was "under consideration" was not just the normal euphemism for a decision that had not yet been announced, but was actually technically true, as at that time he was still talking to Hawker Siddeley and British Rail about buying part of the Hovertrain business. The row deflected attention from the committee's anger at the cancellation decision. Neave's real target, in the view of Heseltine's PPS Cecil Parkinson, was Heath, whom Neave detested and later helped to topple as party leader in 1975, but he and Sir Harry Legge-Bourke, both of whom had distinguished war records, also deplored Heseltine's cutting short of his National Service and his brashness and new money. Heath does not appear to have been overly bothered about the cancellation of Hovertrain, but was bothered about the mooted third London Airport at Maplin Sands on the Essex Coast, which was seen as a major prestige project along with the Channel Tunnel which was begun at this time. The Bill was threatened by a revolt of Tory backbenchers whose seats were affected, and Heath gave Heseltine a dressing down for his lack of energy in promoting it.
Distribution of the Asian citrus psyllid is primarily in tropical and subtropical Asia. It has been reported in all citrus-growing regions in Asia except mainland Japan. The disease has affected crops in China, India, Sri Lanka, Malaysia, Indonesia, Myanmar, the Philippines, Pakistan, Thailand, the Ryukyu Islands, Nepal, Saudi Arabia, and Afghanistan. Areas outside Asia have also reported the disease: Réunion, Mauritius, Brazil, Paraguay, Florida since 2005, and in several municipalities in Mexico since 2009. On 30 March 2012, citrus greening disease was confirmed in a single citrus tree in California. The first report of HLB in Texas occurred on 13 January 2012, from a Valencia sweet orange tree in a commercial orchard in Texas. Prospects are bleak for the ubiquitous backyard citrus orchards of California as residential growers are unlikely to consistently use the pesticides which provide effective control in commercial orchards. The distribution of the African citrus psyllid includes Africa, Madeira, Saudi Arabia, Portugal, and Yemen. This species is sensitive to high temperatures and will not develop at temperatures greater than 25 °C (77 °F). It is a vector of the African strain of huanglongbing (Candidatus Liberibacter africanus), which is sensitive to heat. This strain is reported to occur in Africa, (Burundi, Cameroon, Central African Republic, Comoros, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Reunion, Rwanda, South Africa, St. Helena [unconfirmed], Swaziland, Tanzania, Zimbabwe), Saudi Arabia, and Yemen. The disease was not reported in the EU as of 2004.
Sources: en.wikipedia.org
=== Pharmacokinetics === The bioavailability of tianeptine is approximately 99%. Its plasma protein binding is about 95%. The metabolism of tianeptine is hepatic, via β-oxidation. CYP enzymes are not involved, which limits the potential for drug-drug interactions. Maximal concentration is reached in about an hour and the elimination half-life is 2.5 to 3 hours. The elimination half-life has been found to be increased to 4 to 9 hours in the elderly. Tianeptine is usually packaged as a sodium salt but can also be found as tianeptine sulfate, a slower-releasing formulation patented by Janssen in 2012. In 2022 Tonix Pharmaceuticals received permission from the US FDA to conduct phase II clinical trials on tianeptine hemioxalate extended-release tablets designed for once-daily use. The project was discontinued in late 2023 because of disappointing results in clinical trials. Tianeptine has two active metabolites, MC5 (a pentanoic acid derivative of the parent compound) and MC3 (a propionic acid derivative). MC5 has a longer elimination half-life of approximately 7.6 hours, and takes about a week to reach steady-state concentration under daily-dosing. MC5 is a mu-opioid agonist but not delta-opioid agonist, with EC50 at the mu-opioid receptor of 0.545 μM (vs 0.194 μM for tianeptine). MC3 is a very weak mu-opioid agonist, with an EC50 of 16 μM. Tianeptine is excreted 65% in the urine and 15% in feces.
People's Daily, the official newspaper of the Central Committee of the Chinese Communist Party, said the trip was "Opening up the right path for great powers to coexist" and that "The evolving relationship between China and the United States showcases the fresh air and transformative influence that China, a major eastern power, while steadily marching towards its great rejuvenation, brings to the world". US ambassador to China David Perdue told Fox News that Trump inquired to Xi about selling weapons to China, saying "President Trump continues to say: hey, we sell arms to other people around the world. He actually asked President Xi would he like to buy some at one point?", though American officials subsequently denied plans of weapons sales to China. Regarding Taiwan, Perdue said "We don’t support independence, and we don’t support coercion". When asked by reporters about discussions on Taiwan in the talks, Trump said "We didn’t talk about it too much. Right now, it’s fine. It’s just moving along. We didn’t spend a lot of time talking about Taiwan. He understands very much how I feel". When introducing the results of the visit, the US side used "super intelligence" instead of "artificial intelligence".
The HHS Proficiency Examination (formerly HEW Proficiency Examination) refers to an American medical technologist certification offered by the Department of Health Education and Welfare (HEW) and subsequently United States Department of Health and Human Services (HHS). The examination was established under Social Security Amendments of 1972 and was offered seven times from 1975 until 1987. The HEW/HHS exam qualified individuals to serve as high complexity general supervisors under Clinical Laboratory Improvement Amendments(CLIA) 1992 without a degree. The exam was administered a total of 7 times: 4 times between 1975 and 1977, once in 1979 and once in 1983, and one last time on August 28, 1987. Approximately 65,000 people took the exam, and approximately 31,000 passed. Several other allied health profession proficiency examinations were included in the original act, but only the laboratory examination was renewed. The qualifications for the HEW exam were a GED and 4 year of on-the-job laboratory experience. Over a dozen medical technologist professional associations opposed the certification including the American Society of Clinical Pathologists (ASCP) and American Medical Technologists (AMT). Opposition was in part due to the lack of educational requirements, another competing certification in a crowded field, and a lack of follow-up efficacy.
Sources: en.wikipedia.org
== Manufacturing/packaging == The processes used to manufacture orally disintegrating tablets include loose compression tabletting, a process which is not very different than the manufacturing method used for traditional tablets and lyophilization processes. In loose compression, ODTs are compressed at much lower forces (4 – 20 kN) than traditional tablets. However, since ODTs are compressed at very low forces due to the need for them to be soft enough to disintegrate rapidly in the mouth, issues of material sticking to the die walls can be challenging. Typically, as in most tablet blends, lubricants such as magnesium stearate are added to the blend to reduce the amount of material that may stick to the die wall. Differences may be the use of disintegrating aids, such as crospovidone, and binding agents that aid in mouth feel, such as microcrystalline cellulose. Primarily, ODTs contain some form of sugar such as mannitol, which typically serves as the major diluent of the ODTs, and is also the primary contributor to the smooth and creamy mouth feel of most ODTs. Lyophilized ODT formulations may use proprietary technologies but can produce a tablet that has a faster disintegration rate, for example the Zydis ODT typically dissolves in the mouth in less than 5 seconds without water and Lyophilized Freeze drying tablets - ODT typically dissolves in the mouth in few seconds depending on the molecules and strength. ODTs are available in HPDE bottles (Parcopa) or individually sealed in blister packs to protect the tablets from damage, moisture, and oxidation.
Serotonin, in addition, evokes endothelial nitric oxide synthase activation and stimulates, through a 5-HT1B receptor-mediated mechanism, the phosphorylation of p44/p42 mitogen-activated protein kinase activation in bovine aortic endothelial cell cultures. In blood, serotonin is collected from plasma by platelets, which store it. It is thus active wherever platelets bind in damaged tissue, as a vasoconstrictor to stop bleeding, and also as a fibrocyte mitotic (growth factor), to aid healing.
== Biomedical science in the United Kingdom == The healthcare science workforce is an important part of the UK's National Health Service. While people working in healthcare science are only 5% of the staff of the NHS, 80% of all diagnoses can be attributed to their work. The volume of specialist healthcare science work is a significant part of the work of the NHS. Every year, NHS healthcare scientists carry out:
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.